Quantitative magnetic resonance assessment of brain atrophy related to selected aspects of disability in patients with multiple sclerosis: preliminary results

Ewelina Marciniewicz¹, Anna Pokryszko-Dragan², Przemysław Podgórski¹, Krzysztof Małyszczak³, Anna Zimny¹, Anna Kołtowska¹, Sławomir Budrewicz², Marek Sąsiadek¹, Joanna Bladowska¹

¹Department of General Radiology, Interventional Radiology and Neuroradiology, Wroclaw Medical University, Poland
²Department and Clinic of Neurology, Wroclaw Medical University, Poland
³Division of Psychotherapy and Psychosomatic Medicine, Department of Psychiatry, Wroclaw Medical University, Poland

Abstract

Purpose: The aim of this volumetric study was to evaluate the relationship between brain atrophy quantification in multiple sclerosis (MS) patients and the progression of disability measured by neurological standardised tests.

Material and methods: Seventeen patients (mean age 40.89 years) with clinically definite MS and 24 control subjects (mean age 38.45 years) were enrolled in the study. Brain examinations were performed on a 1.5T MR scanner. Automatic brain segmentation was done using FreeSurfer. Neurological disability was assessed in all patients in baseline and after a median follow-up of two years, using EDSS score evaluation.

Results: In MS patients we found significantly (p < 0.05) higher atrophy rates in many brain areas compared with the control group. The white matter did not show any significant rate of volume loss in MS patients compared to healthy controls. Significant changes were found only in grey matter volume in MS subjects. At the follow-up evaluation after two years MS patients with deterioration in disability revealed significantly decreased cerebral volume in 14 grey matter areas at baseline magnetic resonance imaging (MRI) compared to MS subjects without disability progression.

Conclusions: Grey matter atrophy is associated with the degree of disability in MS patients. Our results suggest that morphometric measurements of brain volume could be a promising non-invasive biomarker in assessing the volumetric changes in MS patients as related to disability progression in the course of the disease.

Key words: multiple sclerosis, magnetic resonance volumetry, neurocognitive dysfunction, EDSS, brain atrophy.

Introduction

Magnetic resonance imaging (MRI) is the method of choice in the diagnosis of multiple sclerosis (MS) as well as in monitoring the disease’s activity [1]. In recent years many researchers have paid much attention to the correlation between radiological findings and clinical state of the patients [2].

In MS the lesion volume reflects the inflammatory feature of the disease, while atrophy measures the quantitatively neurodegenerative aspect of the disease, which play an important role in all disease stages. The issue of brain atrophy in MS patients is not sufficiently reported in the literature with regards to the nature of their clinical significance. A number of studies suggest the role of brain atrophy measures in the prediction of MS progression [1,3,4] (Figure 1).
In our previous review we described the mechanisms that contribute to brain atrophy and important biological factors that can influence the accuracy of brain volume quantification [5]. Atrophy is not only seen within the lesions but also in normal-appearing white matter and grey matter. Brain atrophy is one of the most important indicators of neurodegeneration and clinical disease progression in MS patients and reflects both inflammation-induced axonal loss and post-inflammatory neurodegeneration.

However, longitudinal changes of brain volume and their correlations with clinical worsening in MS have still not been adequately investigated.

In our study we evaluated the relationship between the degree of disability in the course of MS and volumetric brain abnormalities. The primary purpose of this study was to show MRI volumetric features associated with MS. The secondary aim was to compare the results from brain tissue segmentations with clinical parameters assessing the degree of disability using the Expanded Disability Status Scale (EDSS).

**Material and methods**

### Study population

Seventeen patients diagnosed with MS according to the revised McDonald criteria (mean age 52 years, range 34-70 years). Patients were recruited from the Department of Neurology at Wroclaw Medical University between 2014 and 2016. The main demographic and clinical characteristics of the patients are shown in Table 1.

The inclusion criteria for MS patients were: established diagnosis of MS according to 2010 McDonald Criteria, established diagnosis of relapsing remitting multiple sclerosis (RRMS) and disease duration 1-5 years.

Exclusion criteria were concomitant disorders (cerebrovascular disease, neurodegenerative disorder): positive history of alcohol abuse, psychiatric or psychological disorders, and steroid or psychoactive drug treatment in the three months preceding entry to the study.

### Control group

Twenty-four healthy volunteer subjects (11 males, 13 females), age range between 32 and 68 years (mean age 48 years), with no history of neurological or psychiatric disorders were included as the control group. A total of healthy controls were matched to the MS patients regarding age, sex, and educational level, as shown in Table 1.

The study protocol was approved by the Wrocław University Ethics Committee. All the procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

### MR imaging protocols and voxel-based morphometric assessment

Magnetic resonance imaging (MRI) of the cerebrum, cerebellum, and brain stem was performed in 17 individuals with clinically definite multiple sclerosis (MS) and in 24 control subjects. MRI examination was performed on a 1.5 Tesla scanner (Signa Hdx, GE Medical Systems) using a 16-channel head coil. Imaging was done in the coronal, axial, and sagittal planes. Data were transferred to a GE Advantage Workstation and post-processed using fully-automated software Freesurfer image analysis suite version 6.0. On the basis of the volumetric Bravo sequence, brain segmentation was performed. The total brain volume and volume of each region was computed using an interactive image analysis system. A stereotactic atlas was used as a reference for segmenting brain structures.
Bravo is one of the basic acquisition protocols for Automated Brain Segmentation, as we described in our previous paper [6]. The technical parameters of Bravo sequence are as follows: Acquisition time: 5:15 Voxel size: 1.0 × 1.0 × 1.0 mm³, Geometry: FoV 25.6 cm (256 × 256 matrix), 176 sagittal slices, and slice thickness 1 mm. High-resolution, three-dimensional (3D) sequences are preferred for measurement of brain volume because they provide excellent T1w contrast between grey and white matter and are good for showing anatomical details.

Neurological assessment

All patients had a full neurological examination at the time the MRI scans were performed and after a two-year follow-up. The disability assessment was performed using the EDSS (Kurtzke 1983) scale to evaluate the intellectual and functional impairments of MS. The occurrence of clinical multiple sclerosis relapses during the study period was also assessed.

Patients were observed neurologically by the same neurologist, who was unaware of the MRI results. At follow-up evaluations, patients were considered clinically worsened if they had an EDSS score increase of > 0.5 compared to the baseline.

EDSS is the most widely-used measure for assessing the degree of neurological impairment in MS within eight functional systems:
- pyramidal – weakness or difficulty moving limbs,
- cerebellar – ataxia, loss of coordination or tremor,
- brainstem – problems with speech, swallowing, and nystagmus,
- sensory – numbness or loss of sensations,
- bowel and bladder function,
- visual function,
- cerebral (or mental) functions,
- ambulation.

The total score of EDSS ranges from 0 to 10.

At the end of the study we decided to classify the patients according to their cognitive status as follows:
(a) disability regression—patients who presented at least 0.5 improvement from the baseline status in the EDSS test,
(b) disability progression—worsening required at least 0.5 decreased EDSS score from the baseline status,
(c) stable patients—patients not meeting the above-mentioned criteria were classified as stable.

The relationship between atrophy measures and clinical signs was investigated.

All procedures performed in studies involving human participants were in accordance with the ethical standards of Wroclaw Medical University.

Statistical analysis

Statistical analyses were performed to determine associations between volumetric parameters and the degree of disability measured by EDSS for the MS group. Continuous variables were expressed as mean ± standard deviation in the case of normal distribution and median with interquartile range for non-normal distribution. Normality of distribution was verified using the Shapiro-Wilk test. For variables with normal distribution, the ANOVA and Turkey post-hoc tests with correction for non-equal number of cases were used to evaluate differences between the examined groups. The non-parametric Kruskal-Wallis test was used to compare non-normal variables. P values < 0.05 were considered as statistically significant. The median and range of values were reported. STATISTICA software 13.0 (StatSoft) was used for this purpose.

Results

Neurological assessment

Mean EDSS score at baseline was 3.029 (range 1.0-6.0). At the end of the follow-up period we found significant deterioration from baseline data for disability (mean EDSS 3.34, range 1.0-7.0). Overall, seven patients (41.1%) were judged as cognitively worsened (MS1 group – patients with deterioration) at the end of the follow-up, and 10 subjects (58.9%) remained stable (MS0 group – patients without deterioration). There were no patients who showed improvement.

MRI and brain volume changes

Whole brain volume measurement has been established as a robust measure to differentiate the level of atrophy in MS patients, compared to age- and sex-matched healthy individuals. Compared with healthy controls, MS patients during the follow-up period displayed significant decrease in brain parenchymal volumes in several areas within grey matter. Regions of significant brain parenchymal volume changes are presented in Table 2.

Figures 2, 3, and 4 present a comparison of volumes of selected cerebral areas in particular groups.

The white matter did not show a significant rate of volume loss in MS patients compared to healthy controls.

When we compared the rate of volume loss across different regions in all MS patients together, compared with CG, the greater decline was observed in the four grey matter regions – Table 2.

Comparison of the MS0 (patients without deterioration) and CG groups

Compared with the healthy control group, MS patients without progression showed significantly higher volume loss within the following four areas: left straight gyrus (gyrus rectus) \( p = 0.021 \), left planum polare of the superior temporal gyrus \( p = 0.028 \), horizontal ramus of the lateral sulcus \( p = 0.030 \), and left Broca’s area \( \text{pars triangularis} \) \( p = 0.097 \).
Comparison of the MS1 (patients with deterioration) and CG groups

Significantly higher volume loss in MS patients with progression compared with healthy controls was observed within 14 grey matter areas (Table 3).

Comparison of the MS1 (patients with deterioration) and MS0 groups (patients without deterioration)

Significantly higher volume loss was found in MS patients with progression compared to those with stable disease in several areas (Table 3).

Discussion

Multiple sclerosis is a chronic autoimmune disease that causes neurological problems and results in progressive disability.

Multiple sclerosis-related brain atrophy is a consequence of both underlying pathology (neuroinflammation) and neuroaxonal loss. Brain volume loss in MS patients occurs at a faster rate than in the healthy population: 0.5-1.0% vs. 0.1-0.3% per year [7,8]. Atrophy may be found early in the disease course even before clinical symptoms and lead to long-term neurological disability [9,10].

Magnetic resonance imaging (MRI) is an important tool not only in the process of diagnosis but also in the monitoring of disease activity and predicting treatment efficacy [11]. In the literature there is still inconsistency regarding MRI protocols and the frequency of neurological examinations.

The primary objective of this study was to evaluate the correlation between MR-based quantitative brain volume changes and clinical deterioration in the course of MS [12].

There are several freely available tools for automated brain volumetry that are commonly used in MS patients. In our study we chose one of the most popular software packages – FreeSurfer [13-16]. These automated techniques express the results as a percentage of the change in brain volume.

Until now, EDSS has been a widely-accepted measure of clinical disability in MS patients and can provide useful information about the clinical state of the patients.

There are several limitations when using EDSS alone as an outcome measure. First of all it is based on neurological examination, which is inherently subjective [17]. Furthermore, the number of relapses strongly depends on the frequency of medical visits during the trial duration [18,19]. These factors may confound the interpretation of relapse rate reduction in treatment trials. Also, the clinical state of the patient does not reflect the true activity of MS in the central nervous system [20]. These factors potentially limit the use of EDSS as a separate measure.

Our study demonstrated that a remarkable part of the study population had worsening disability (41%). These
correlations existed throughout the disease course and in all clinical phenotypes.

The white matter did not show a significant rate of volume loss in MS patients and healthy controls. Our results are consistent with other reports [8] indicating that relationships between whole brain atrophy and clinical changes are weak or absent. Overall cognitive impairment did not correlate significantly with age, disease duration, and type of treatment.

The more detailed post-hoc analyses showed the following baseline grey matter volumes: right somatosensory area (p = 0.000538), paracentral lobule (p = 0.007), right short insular gyr (p = 0.007), and left Broca’s area (pars triangularis) (p = 0.003) were associated with future

### Table 3. Mean volumes of certain brain structures different groups: multiple sclerosis group without neurological deterioration (MS0), with neurological progression (MS1), and control group (CG). Turkey test with correction for non-equal groups. *Kruskall Wallis test

| Brain region | Mean MS0 | Mean MS1 | Mean CG | MS0 vs. CG | MS1 vs. CG | MS1 vs. MS0 |
|--------------|----------|----------|---------|------------|------------|------------|
| Left Broca’s area (pars triangularis) | 3776.4 | 4223.8 | 0.0062 |
| Right somatosensory area | 2307.5 | 2482.5 | 0.0423 |
| Right Broca’s area (pars opercularis) | 7171.5 | 8099.2 | 0.0197 |
| Right primary motor area (anterior) | 2761.0 | 3112.9 | 0.0122 |
| Right superior temporal sulcus (parallel sulcus) – grey matter volume | 7911.2 | 8948.00 | 0.0404 |
| Right lateral orbital sulcus – grey matter volume | 489.0 | 621.2 | 0.0035 |
| Left insula cortex – grey matter volume | 5968.4 | 6404.5 | 0.0499 |
| Left lateral division of orbitofrontal cortex – grey matter volume | 2866.1 | 3237.5 | 0.0177 |
| Right orbital gyri – grey matter volume | 5786.8 | 6261.7 | 0.0373 |
| Left orbital gyri – grey matter volume | 5336.1 | 5807.1 | 0.0475 |

*p < 0.05 was set as statistically significant.
EDSS progression. Our findings suggest that volume loss of these regions might become biomarkers of clinical disability progression. From all of them the right somatosensory area volume had the highest predictive value of EDSS progression during follow-up ($p = 0.000538$).

The primary somatosensory cortex is located in the postcentral gyrus in the parietal lobe and is responsible for processing somatic sensations – detecting touch, proprioception, and temperature. The somatosensory cortex receives all sensory input from the opposite side of the body. The damage in this area results in ignorance of certain body regions or even agnosia. On the basis of the above results, we put forward a hypothesis that impairments in somatosensory function may be the most sensible to atrophy and become an indicator of neurological impairment in multiple sclerosis.

These differences in mean volume values should be regarded as not significant, due to the small size of the groups and low power calculations: about 0.5 for $t$-tests for dependent variables (comparisons before and after treatment) and about 0.25 for independent variables (comparisons with the control group). We therefore plan to repeat the measurements on the same scanner and on a larger cohort of patients to confirm our preliminary results.

The recent findings support the importance of the early use of disease modifying therapy in clinically asymptomatic patients without remarkable physical disability. Clinical assessment can be improved by using EDSS in conjunction with MRI measures. Furthermore, the quantification of atrophy rate may become a useful outcome measure in neuroprotective clinical trials.

The importance of measuring brain atrophy in the course of MS is widely raised in the literature. Zivadinov et al. investigated the association between cortical and subcortical volume changes and disability progression [21]. After five years of follow-up, patients with sustained disability progression (SDP) had significantly greater percentage of atrophy rates compared with those without SDP in the whole brain volume ($p < 0.0001$), cortex ($p = 0.001$), total grey matter ($p = 0.003$), and thalamus ($p = 0.01$). The same author reported also that thalamic atrophy and increase in lateral ventricle volumes in clinically isolated syndrome (CIS) is associated with an increased risk of conversion to MS [22].

In our previously published review we analysed the then current available evidence regarding the role of brain atrophy measurements and its consequence in MS patients [23]. Grey matter atrophy develops faster than white matter atrophy and correlates with physical and cognitive disability.

Calabrese et al., in their study, suggested an association between cortical and deep grey matter atrophy and the development of fatigue in relapsing-remitting multiple sclerosis. A significant atrophy of striatum, thalamus, superior frontal gyrus, and inferior parietal gyrus was observed in fatigued patients compared with non-fatigued patients [24].

Similar findings were observed by Batista et al. [25], who reported a slower information-processing speed measured by the Paced Auditory Serial Addition Test (PASAT) and the Symbol Digit Modalities Test (SDMT) in those with greater atrophy of subcortical structures including the thalamus and the caudate.

Our study was not designed to assess the effect of treatment on atrophy rates; nevertheless, all the patients were receiving disease modifying treatments during the entire study period. The majority (82%) of patients were receiving interferon or fingolimod.

Therefore we are not certain whether the treatment administration influences the accuracy of brain atrophy quantification, although in the literature we found many reports confirming that the rates of atrophy in all clinical phenotypes were similar in people who were receiving disease-modifying treatments to those who were not [8,26]. We suppose that drug effects are unlikely to be confounders of our analysis.

The quantitative magnetic resonance-based techniques are potentially valuable outcome measures in MS. In the last decade there have been a number of reports considering brain atrophy as an important endpoint for determining future progression of physical and cognitive disability and for assessing the efficacy of disease-modifying treatment [27-29]. Such innovative techniques are potentially valuable. They allow multiple or continuous assessment, which might give a more adequate picture of a patient’s disability and the impact of the disease on daily life.

However, the assessment of brain atrophy is still not included in the standard clinical monitoring of MS patients. Identification of progression or neurodegenerative changes remains very challenging. There is an increasing need to define simple, accurate, and reproducible brain volume measures that can be used in clinical routine.

The main strength of our report is the use of a quantitative assessment of MRI and its correlation with clinical parameters, which provides additional insight into disease activity in MS.

Our study also has some limitations, mainly concerning the small number of patients. There is a fear that such a sample size might be too small to ensure adequate power. Nevertheless, this study is a preliminary study with a relatively small sample size and short follow-up period, and we plan to continue our research.

All the examinations were performed by the same experienced neurologist specialising in multiple sclerosis, who was unaware of the MRI results. The same tests were used at the baseline and at the end of the two years of follow-up. We have provided robust measures of the whole brain volume. All patients underwent the same protocol and on the same MRI scanner over time.

What is of interest is that the volumetric parameters were measured once. Considering that atrophy accumulates slowly over time, longer follow-up is needed to detect significant changes. Secondly, anti-inflammatory therapies...
may cause a decrease in brain volume due to the resolution of inflammation and oedema and should not be regarded as true neurodegeneration. This effect, called pseudoatrophy, may last up to one year after initiation of treatment [30-32].

Therefore, further studies with larger sample sizes and longer follow-up at two different time points are warranted to confirm our results.

While there is a need to translate measurement of brain atrophy to clinical routine at the individual patient level, there are still a number of challenges that must be overcome, including biological confounding factors such as ageing, dehydroxylation, and menstrual cycle. Brain volume changes in MS are the result of volume-gaining and volume-losing processes – neuroinflammation, neurodegeneration, and remyelination. Nevertheless, we strongly highlight the opinion that MRI-based volumetry should commonly be used in everyday clinical practice because it provides comprehensive characteristics of a patient’s clinical status.

Conclusions

In conclusion, our results indicate that the loss of grey matter in multiple sclerosis could be one of the essential factors responsible for progression of physical disability and cognitive deterioration in the course of the disease. The use of the EDSS score, together with MRI volumetric measures, ensures a reliable correlation between radiological appearance and clinical state and provides the best characteristic of functional impairments in MS. MRI-based volumetry could be an attractive non-invasive neuroimaging biomarker in the prediction of future disability progression. Therefore, it should be used inseparably in a clinical routine in order to identify patients at the highest risk of disease progression as soon as possible.

Conflict of interest

None of the authors declared any conflict of interest.

References

1. Cahalane MA, Kearney H, Purcell YM, et al. MRI and multiple sclerosis – the evolving role of MRI in the diagnosis and management of MS: the radiologist’s perspective. Ir J Med Sci 2018; 187: 781-787.
2. Kearney H, Cahalane AM, Killeen RP, McGuigan C. MRI and multiple sclerosis – the evolving role of MRI in the diagnosis and management of MS: a clinician’s perspective. Ir J Med Sci 2018; 187: 493-498.
3. Arevalo O, Riascos R, Rabiei P, et al. Standardizing Magnetic Resonance Imaging Protocols, Requisitions, and Reports in Multiple Sclerosis: A Update for Radiologist Based on 2017 Magnetic Resonance Imaging in Multiple Sclerosis and 2018 Consortium of Multiple Sclerosis Centers Consensus Guidelines. J Comput Assist Tomogr 2019; 43: 1-12.
4. Vågberg M, Axelsson M, Birgander R, et al. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurol Scand 2017; 135: 17-24.
5. Marciniwicz E, Podgórski P, Sąsiadek M, Błażowska J. The role of MR volumetry in brain atrophy assessment in multiple sclerosis: A review of the literature. Adv Clin Exp Med 2019; doi:10.17219/acem/94137 [In press].
6. Marciniwicz E, Podgórski P, Pawłowski T, et al. Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study. J Neurol Sci 2019; 399: 36-43.
7. Zivadinov R, Scepic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 773-780.
8. Eshaghi A, Prados F, Brownlee WJ, et al., on behalf of the M. study MAGNIMS study group. Deep gray matter volume loss disabiity worsening in multiple sclerosis. Ann Neurol 2018; 83: 210-222.
9. Megna R, Alfano B, Lanzillo R, et al. Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment. J Neurol 2019; 266: 361-368.
10. Furby J, Hayton T, Anderson V, et al. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler J 2008; 14: 1068-1075.
11. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121 (Pt 1): 3-24.
12. De Stefano N, Stromillo ML, Giorgio A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 03-99.
13. Popescu V, Agosta F, Hulst HE, et al., MAGNIMS Study Group, Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84: 1082-1091.
14. Guo C, Ferreira D, Fink K, et al. Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis. Eur Radiol 2019; 29: 1355-1364.
15. Chu R, Kim G, Tauhid S, et al. Whole brain and deep grey matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. PLoS One 2018; 13: e0206939.
16. Destrieux C, Fischl B, Dale A, Halgren E. Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage 2010; 51: 1-15.
17. Goodkin DE, Cookefair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology 1992; 42: 859-863.
18. Whitaker J, McFarland H, Rudge P, Reingold S. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler J 1995; 1: 37-47.
19. Saccà F, Costabile T, Carotenuto A, et al. The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests. Mult Scler J 2017; 23: 1289-1296.
20. Raji A, Ostwaldt AC, Opfer R, et al. MRI-Based Brain Volumetry at a Single Time Point Complements Clinical Evaluation of Patients With Multiple Sclerosis in an Outpatient Setting. Front Neurol 2018; 9: 545.
21. Zivadinov R, Bergsland N, Dolezal O, et al. Evolution of cortical and thalamic atrophy and disability progression in early relapsing-remitting MS during 5 years. AINR Am J Neuroradiol 2013; 34: 1931-1939.
22. Zivadinov R, Havrdová E, Bergsland N, et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013; 268: 831-841.
23. Marciniewicz E, Podgórski P, Sąsiadek M, Bladowska J. The role of MR volumetry in brain atrophy assessment in multiple sclerosis: A review of the literature. Adv Clin Exp Med 2019; doi:10.17219/acem/94137 [In press].
24. Calabrese M, Rinaldi F, Grossi P, et al. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler 2010; 16: 1220-1228.
25. Batista S, Zivadinov R, Hoogs M, et al. Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 2012; 259: 139-146.
26. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496.
27. Anderson VM, Fernando KT, Davies GR, et al. Cerebral Atrophy Measurement in Clinically Isolated Syndromes and Relapsing Remitting Multiple Sclerosis: A Comparison of Registration-Based Methods. J Neuroimaging 2007; 17: 61-68.
28. Anderson VM, Bartlett JW, Fox NC, et al. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. J Neurol 2007; 254: 1588-1594.
29. Bergsland N, Horakova D, Dwyer MG, et al. Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. Am J Neuroradiol 2012; 33: 1573-1578.
30. Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013; 19: 1175-1181.
31. De Stefano N, Arnold DL. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Mult Scler 2015; 21: 675-676.
32. Zivadinov R, Jakimovski D, Gandhi S, et al. Clinical relevance of brain atrophy assessment in multiple sclerosis: Implications for its use in a clinical routine. Expert Rev Neurother 2016; 16: 777-793.